Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients
- 257 Downloads
In order to analyze the clinicopathological features of Chinese triple negative tumors, we performed a retrospective study of 1993 female unilateral breast cancer patients undergoing surgery in Cancer Hospital of Fudan University, Shanghai, China. Survival curves were performed with Kaplan–Meier method and annual recurrence hazard was estimated by hazard function. We observed that the rate of larger tumors in triple negative patients was higher than that in HR+/ERBB2− women, but lower than that in ERBB2+ subgroup (P = 0.0001). In addition, 21.83% of triple negative patients had four or more axillary lymph nodes involved as compared to 27.40% of ERBB2+ women and 22.75% of HR+/ERBB2− subgroup (P = 0.0056). In the survival analysis, we found a statistical significance for recurrence-free survival (RFS) among the three subgroups (P = 0.0037), with the rate of 72.89% for ERBB2+ patients, 78.40% for HR+/ERBB2− ones and 75.76% for triple negative ones at the 11th year respectively. When it came to hazard peaks, discrepancies existed in different subgroups. Similar to HR+/ERBB2− patients, triple negative subgroup showed an early major recurrence surge peaking at approximately year 2.5 as opposed to ERBB2+ counterparts with a tapering sharp at the 1st year. Furthermore, the first peak of triple negative tumors was higher than that of HR+/ERBB2− patients, but lower than that of ERBB2+ ones. Therefore, our findings suggested biological characteristics and prognostic outlook of Chinese triple negative breast cancers might be more favorable and somewhat different from those in Western populations.
KeywordsBreast neoplasm Triple negative Recurrence hazard
The authors thank the family members for their willingness to cooperate with our study. This research was supported in part by the grants from the National Basic Research Program of China (2006CB910501), National Natural Science Foundation of China (30371580, 30572109); Shanghai Science and Technology Committee (03J14019, 06DJ14004, 06DZ19504).
- 6.Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Paper presented at the 28th San Antonio Breast Cancer Symposium, Henry B. Gonzalez Convention Center, San Antonio, Texas, USA, 8–11 December 2005Google Scholar
- 11.Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728. doi: 10.1002/cncr.22618 PubMedCrossRefGoogle Scholar
- 15.Carey LA, Dees EC, Sawyer L et al (2004) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 15:2329–2334Google Scholar
- 17.Chang BW, Decker RH, Haffy BG et al (2007) Incidence of brain metastases in early-stage triple negative breast cancer patients. Paper presented at the 49th American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting, Los Angeles, California, USA, 28 October–1 November 2007Google Scholar
- 20.Howell A on behalf of the ATAC Trialists’ Group (2005) Author’s reply. Lancet 365:1225–1226Google Scholar
- 30.Zahl PH, Tretli S (1997) Long-term survival of breast cancer in Norway by age and clinical stage. Stat Med 16:1435–1449. doi :10.1002/(SICI)1097-0258(19970715)16:13<1435::AID-SIM570>3.0.CO;2-8Google Scholar
- 32.Olopade OI, Ikpatt FO, Dignam JJ et al (2004) “Intrinsic Gene Expression” subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry. Paper presented at American Society of Clinical Oncology Annual Meeting, New Orleans, Louisiana, USA, 5–8 June 2004Google Scholar
- 33.Nishimura R, Arima N (2008) Is triple negative a prognostic factor in breast cancer? Breast Cancer (in press). doi: 10.1007/s12282-008-0042-3
- 34.Lund MJ, Trivers KF, Porter PL et al (2008) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat (in press). doi: 10.1007/s10549-008-9926-3
- 38.Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350. doi: 10.1002/ijc.21004 PubMedCrossRefGoogle Scholar
- 58.Kilburn LS on behalf of the TNT Trial Management Group (2007) ‘Triple Negative’ Breast Cancer: a new area for Phase III breast cancer clinical trials. Clin Oncol (R Coll Radio) 20:35–39. doi: 10.1016/j.clon.2007.09.010